Serum matrix metalloproteinase-3 levels are elevated in myasthenia gravis
| Autor: | Steven P. Luckman, Fredrik Romi, Nils Erik Gilhus |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Matrix Metalloproteinase 3
medicine.medical_specialty Immunology Neuromuscular transmission Neuromuscular junction Internal medicine Myasthenia Gravis Humans Immunology and Allergy Medicine Acetylcholine receptor Chi-Square Distribution Agrin business.industry Muscle weakness medicine.disease Myasthenia gravis medicine.anatomical_structure Endocrinology Neurology Rheumatoid arthritis Neurology (clinical) medicine.symptom business |
| Zdroj: | Journal of Neuroimmunology. 195:96-99 |
| ISSN: | 0165-5728 |
| DOI: | 10.1016/j.jneuroim.2007.10.018 |
| Popis: | MMP-3 is capable of degrading a variety of proteins, including agrin, which plays a critical role in neuromuscular signalling by controlling acetylcholine receptor clustering. The degradation of agrin by MMP-3 may disrupt the neuromuscular junction leading to a failure of neuromuscular transmission and muscle weakness. We have therefore examined the levels of MMP-3 in 116 patients with myasthenia gravis (MG) and 90 healthy controls. A significant elevation in MMP-3 levels was observed in 10% of seronegative and 17% of seropositive MG patients, indicating that MMP-3 may play a pathogenic role in a proportion of MG patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect